PULSE OXIMETRY FOR HOME USE

Policy

VCHCP considers pulse oximeters to be durable medical equipment (DME)\(^1\)

VCHCP covers pulse oximetry for home use only in the following conditions and after Medical Director Review:

1. When weaning the patient from home oxygen
2. When a change in the patient’s physical condition requires an adjustment in the liter flow of their home oxygen needs
3. To determine appropriate home oxygen liter flow for ambulation, exercise, or sleep
4. Pulse oximetry can be used in conjunction with infant home apnea monitoring.

Coverage of home pulse oximetry for indications other than those listed above may be approved on a case-by-case basis after review by a medical director.

VCHCP does **NOT** cover the use of home pulse oximetry in the following conditions:

1. asthma management
2. when used alone as a screening/testing technique for suspected obstructive sleep apnea

Background

For patients on long-term oxygen therapy, pulse oximetry Sa02 measurements are unnecessary except to assess changes in clinical status, or to facilitate changes in the oxygen prescription. Home pulse oximetry is also indicated when there is a need to monitor the adequacy of Sa02 or the need to quantitate the response of Sa02 to a therapeutic intervention.

An NHLBI/WHO Global Asthma Initiative Report concluded that pulse oximetry was not an appropriate method of monitoring patients with asthma. The report explained that during asthma exacerbations, the degree of hypoxemia may not accurately reflect the underlying degree of ventilation-perfusion (V–Q) mismatch.

---

\(^1\) DME is subject to an annual maximum for some plans.
Pulse oximetry alone is not an efficient method of screening or diagnosing patients with suspected obstructive sleep apnea. The sensitivity and negative predictive value of pulse oximetry is not adequate to rule out obstructive sleep apnea in patients with mild to moderate symptoms. Therefore, a follow up sleep study would be required to confirm or exclude the diagnosis of obstructive sleep apnea, regardless of the results of pulse oximetry screening.

Unless indicated otherwise above, this policy applies unless a specific limitation or exception exists.

**ICD-9 Codes/CPT Codes:**

**ICD-9 Codes:**

This is not a complete list of ICD-9 Codes

- 277.00-Cystic fibrosis
- 289.0-Erythrocytosis
- 413.9-Angina pectoris
- 416-Chronic pulmonary heart disease
- 416.0-Pulmonary hypertension
- 416.9-Chronic cor pulmonale
- 428.0-Congestive heart failure
- 443.9-Peripheral vascular disease, unspecified
- 492-Emphysema
- 494-Bronchiectasis
- 496-Chronic obstructive pulmonary disease
- 515-Postinflammatory pulmonary fibrosis
- 786-Dyspnea and respiratory abnormalities
- 799.0-Hypoxemia

**CPT Codes:**

- 94760-Noninvasive ear or pulse oximetry for oxygen saturation; single determination
- 94761-multiple determinations (e.g., during exercise)
- 94762-by continuous overnight monitoring

**Place of Service:**

Home

**A. Attachments:** None
B. References:


C. History:

Reviewers: Richard O. Ashby MD, Thomas Brugman MD, QA Committee
Reviewed/Revised: Faustine Dela Cruz, RN & Albert Reeves, MD; Date: 11/7/11
Committee Review: UM on 11/10/11 QAC on 11/22/11
Reviewed/No Changes: Albert Reeves, MD; Date: 4/17/12
Committee Reviews: UM on 5/10/12 & QA on 5/22/12
Reviewed/No Changes: Albert Reeves, MD; Date: 1/28/13
Committee Review: UM on 2/14/13; QA on 2/26/13
Reviewed/No Changes: Catherine Sanders, MD
Committee Review: UM on 2/13/14; QA on 2/25/14
Reviewed/No Updates: Catherine Sanders, MD
Committee Review: UM on 02-12-2015 & QA on 02-24-2015
Reviewed/No Updates by: Faustine Dela Cruz, RN & Catherine Sanders, MD
Reviewed/No Updates by: Catherine Sanders, MD & Robert Sterling, MD
Medical Policy: **Pulse Oximetry for Home Use**

Effective November 8, 2001
Reviewed: November 7, 2011; April 17, 2012
Reviewed/No Updates: 1/28/13; 2/13/14; 2/12/15;
2/11/16; 2/9/17; 2/8/18; 2/14/19; 2/13/20

Reviewed/No Updates by: Catherine Sanders, MD & Robert Sterling, MD
Committee Review: UM: February 8, 2018; QAC: February 27, 2018
Reviewed/No Updates by: Catherine Sanders, MD & Robert Sterling, MD
Committee Review: UM: February 14, 2019; QAC: February 26, 2019
Reviewed/No Updates by: Howard Taekman, MD & Robert Sterling, MD

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/9/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
<tr>
<td>2/8/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
<tr>
<td>2/14/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
<tr>
<td>2/13/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual Review</td>
</tr>
</tbody>
</table>